Table 2.
During cycles 1–2 of 17β-estradiola | During alternating Txa | |
---|---|---|
n (%) | n (%) | |
Best response by RECIST PR |
2 (10.5)b | 3 (15.8)b |
SD | 12 (63.2) | 5 (26.3) |
Disease progression | 5 (26.3) | 11 (57.9) |
Total evaluable | 19 (100.0) | 19 (100.0) |
Clinical benefitc | — | 8 (42.1) |
Response as measured compared with baseline.
One PR was nonconfirmed.
Defined as SD ≥ 24 weeks or PR.